Eric Schmidt

Roy Buchanan

Seamus Fernandez

Edward Marks

Gregory Renza

Joseph Stringer

Sara Nik

- Cidara Therapeutics, Inc. is proceeding with an **expanded and accelerated development plan** for its CD388 Phase 3 registrational trial, aiming for biologics license application (BLA) approval based on a single study.  **[1610618_0001193125-25-214001_d159459d8k.htm:1]** 
- The study population for CD388 will be expanded to include adults over 65 years of age without specific co-morbidities, in addition to subjects over 12 years of age with high-risk comorbidities or immune-compromised status, significantly increasing the **potential U.S. patient pool from approximately 50 million to over 100 million people**.  **[1610618_0001193125-25-214001_d159459d8k.htm:1]** 
- Enrollment for the global Phase 3 study, targeting **6,000 subjects**, is set to begin by the **end of September 2025** in the Northern Hemisphere, representing a **six-month acceleration** from the prior plan.  **[1610618_0001193125-25-214001_d159459d8k.htm:1]** 
- The company believes its **existing cash, cash equivalents, and restricted cash will be sufficient to fully fund the planned Phase 3 development program through completion**.  **[1610618_0001193125-25-214001_d159459d8k.htm:1]**

Cidara Therapeutics (CDTX)